What treatment should be given for multiple sclerosis at the present time?;Que tratamiento debemos emplear actualmente en la esclerosis multiple?

Revista de Neurologia

Volumn 30, Issue 10, 2000, Pages 993-995

  Ramo Tello, C ^a   Leon Colombo T ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Corticosteroids; Interferons; Multiple sclerosis; Treatment

Indexed keywords

AZATHIOPRINE; BETA1 INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; MYELIN; VACCINE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; STEROID;

ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIPLE SCLEROSIS; ACUTE DISEASE; REVIEW;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; INTERFERONS; MULTIPLE SCLEROSIS; STEROIDS;

EID: 0034673902     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3010.99372     Document Type: Article

References (11)

1. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-9.
2. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-34.
3. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6.
4. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
5. Paty DW, Li DKW, The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43: 662-7.
6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1996; 39: 285-94.
7. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, et al. Magnetic resonance imaging changes with recombinant human interferon b-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-8.
8. th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 2-5 November 1997, Istambul, Turkey.
9. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
10. Hughes RAC. Treatment of multiple sclerosis with azathioprine. In Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis. London: Springer-Verlag; 1992. p. 157-72.
11. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment of multiple sclerosis. Lancet 1991; 338: 1051-5.